DFMO, an irreversible inhibitor of ornithine decarboxylase (ODC), is under development as a chemopreventive drug against cancers with pronounced proliferative phases. In support of human clinical trials, preclinical developmental toxicity studies were conducted in pregnant rats and rabbits. Rats were treated during GD 6 -17, and fetuses were obtained by C-section on GD 20. Rabbits were treated during GD 7-20, and fetuses were obtained by C-section on GD 29. The dose range-finding study in rats (5/group at 0, 50, 125, 300, 800, or 1000 mg/kg/day) revealed maternal toxicity at doses > 800 mg/kg/day (decreased body weights and food consumption) and developmental toxicity at doses > 300 mg/kg/day (increased early resorptions and reduced fetal body weights). In the main study, rats (25/group) received 0, 30, 80, or 200 mg/kg/day. Developmental toxicity in the absence of maternal toxicity was observed at 200 mg/kg/day as significantly decreased fetal weights and increased incidence of litters with skeletal variations of 14th rudimentary rib, 14th full rib, and/or 27th presacral vertebrae. There were no treatment-related fetal skeletal malformations or external or visceral anomalies at any dose level. The dose range-finding study in rabbits (5/group at 0, 30, 60, 120, 240, or 500 mg/kg/day) revealed developmental toxicity at doses > 60 mg/kg/day (increased resorptions and reduced fetal body weights) in the absence of maternal toxicity. In the main study, rabbits (20/group) received 0, 15, 45, or 135 mg/kg/day. Developmental toxicity in the absence of maternal toxicity was observed at 135 mg/kg/day as nonsignificantly increased early resorptions, decreased implantation sites, decreased viable fetuses, and reduced fetal weights. There were no external, visceral, or skeletal anomalies at any dose level. Thus, in the main developmental toxicity studies, DFMO produced developmental but not maternal toxicity at 200 and 135 mg/kg/day in rats and rabbits, respectively. Accordingly, in rats, the maternal no-observableeffect level (NOEL) was 200 mg/kg/day and the fetal NOEL was 80 mg/kg/day; while in rabbits the maternal NOEL was 135 mg/kg/ day and the fetal NOEL was 45 mg/kg/day. These fetal NOELs are several-fold higher than the dose level currently used in Phase II and III clinical trials (ϳ13 mg/kg).
Polyamines such as putrescine, spermidine, and spermine are nucleotide precursors that are present in all mammalian cells and are essential to maintenance of cell growth and function Ghoda et al., 1992; Heby, 1981; Pegg, 1988; Pegg et al., 1987) . Polyamine synthesis occurs during the G1 phase of the cell cycle, i.e., the period between mitosis and DNA synthesis (Heby, 1981) . The initial step in polyamine synthesis and subsequent cell proliferation is the decarboxylation of L-ornithine by ODC, which results in the conversion of ornithine to putrescine, the precursor of spermidine and spermine (Ghoda et al., 1992; Heby, 1981; Pegg et al., 1987; Tabor and Tabor, 1984) . Basal activity of ODC is typically low with increased ODC activity noted after the cell's entry into the G1 phase (Heby, 1981) . Increased ODC activity and concomitantly increased levels of polyamines are found in proliferating cells such as those found in tumors and embryos (Fozard et al., 1980a,b; Luk and Casero, 1987; Pegg et al., 1987) . ODC is induced by chemical carcinogens, thus suggesting that the enzyme participates in the process of carcinogenesis (Luk et al., 1986; Yuspa et al., 1976) . Based on these observations, inhibition of ODC has been considered an effective approach in cancer chemotherapy (Pegg et al., 1987) .
DFMO [2-(Difluoromethyl)-dl-ornithine, also known as ␣-difluoromethylornithine, difluoromethylornithine, eflornithine HCL, ornidyl, or RMI 71782] is a potent, irreversible inhibitor of ODC. DFMO was developed for treatment of Trypanosoma brucei gambiense, the parasite which causes African sleeping sickness and is effective via suppression of trypanosome DNA synthesis (Pegg, 1988; Pegg et al., 1987; Ghoda et al., 1992) . The cancer chemopreventive potential of DFMO has been evaluated in vitro and in vivo. In the presence of DFMO, neoplastic cellular proliferation was retarded along with substantial decreases in the content of cellular putrescine and spermidine (Pegg et al., 1987) . Significant antiproliferative effectiveness was also demonstrated against chemical carcin-ogen-induced tumors in animal models (Steele et al., 1994) including bladder (Moon et al., 1992) , colon (Kingsnorth et al., 1983) , mammary gland (Ratko et al., 1990; Thompson et al., 1984) , liver (Moore et al., 1984) , stomach (Newberne et al., 1987) , and skin (Takigawa et al., 1983; Weeks et al., 1982) .
DFMO is currently in Phase II clinical trials sponsored by the National Cancer Institute as a chemopreventive agent against cancers with pronounced proliferative phases such as colon, breast, cervix, and esophageal cancer, and in Phase III clinical trials for the prevention of recurrent bladder cancer (Crowell, personal communication; Kelloff et al., 1994a,b,c) . Completed clinical trials have established a baseline, welltolerated oral dose of 0.5 g/m 2 /day (13 mg/kg body weight) administered for 10 -12 months (Creaven et al., 1993; Love et al., 1993) . An infrequent adverse effect of loss of hearing acuity was reversible upon cessation of treatment. Preclinical safety studies up to 1-year in rats and dogs have been completed . In order to support further development of DFMO as an antiproliferative, chemopreventive agent, preclinical safety studies were conducted in rats and rabbits to evaluate the potential for developmental toxicity.
MATERIALS AND METHODS
Test compound. 2-(Difluoromethyl)-dl-ornithine monohydrochloride monohydrate ; from McKesson BioServices, Rockville, MD) was stored at room temperature and humidity and protected from light. The drug was initially identified by GC-MS. The purity, determined by HPLC prior to and following completion of the in-life phase of each study, was approximately 89 -90%. Thus, the drug was stable under storage conditions. Specific identity of the impurities was not determined. DFMO dosing solutions were prepared individually with the required amount of vehicle (deionized distilled water) and stored at 2-8°C. Samples of dosing solutions prepared weekly were analyzed by HPLC to determine the actual concentrations of DFMO prior to use. Only solutions within 10% of theoretical (i.e., target) concentration were used. DFMO solutions were stable for 16 days under refrigeration at concentrations of 1-200 mg/ml with periodic sampling under the conditions of use.
Animals and husbandry.
The studies were conducted in accordance with the Food and Drug Administration Good Laboratory Practice (GLP) Regulations for Nonclinical Laboratory Studies (FDA, 1978) . The protocols for these studies were in accordance with the FDA Guideline on Detection of Toxicity to Reproduction for Medicinal Products (1994) which was prepared under the auspices of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, and were approved by the University of Illinois at the Chicago Animal Care and Use Committee.
Rat study. Time-mated Crl:CD BR (VAF) albino rats (ϳ9 weeks old) were obtained from Charles River Breeding Laboratories (Portage, MI). Virgin females were placed with proven male breeders for 1 to 3 sequential nights. The morning when the vaginal plug was found was considered GD 0, and the presumed pregnant females were returned to their homecage. Animals were identified (i.e., ear tagged) and weighed by the supplier (GD 0 weight range 191-210 g). Upon arrival at the UIC AAALAC International accredited facility, the animals were at GD 1, GD 2, or GD 3. All animals were quarantined for at least 3 days before initiation of dosing, observed daily for signs of illness, and approved for use by the clinical veterinarian prior to being placed on study. The rats were singly housed in polycarbonate cages (840 cm 2 area and 20 cm height) with stainless steel cage tops and Anderson Bed-a-cob bedding (Heinold Co., Kankakee, IL). Environmental controls were set to maintain temperature (65-78°F), humidity (30 -70%), and a 14-h-light/10-hdark cycle. Certified Rodent Chow No. 5002 (PMI Feeds, Inc., St. Louis, MO) was supplied ad libitum and tap water from an automatic watering system was available from arrival to study termination.
Animals from each GD 0 subset were randomized by body weight into 4 groups, to result in 25 per group. The drug was administered by gavage, once daily, at doses of 30, 80, or 200 mg/kg/day (dose volume 10 ml/kg body weight/day) over GD 6 -17. The gavage procedure was accomplished by use of a rigid oral feeding needle. The control group received the vehicle (deionized distilled water) at the same dosing volume. The specific volume administered was adjusted on the basis of the animal's daily pre-dose body weight. Nonfasted body weights were recorded on GD 0 (by the supplier), on the day of randomization (GD 5), daily during the dosing period , and during the post-dosing period (GD 20) . Food consumption was recorded during the following intervals: GD 6 -12, 12-17, and 17-20. Clinical signs were observed and recorded approximately 1-2 hours post-dosing on the days of dosing, and each morning following completion of the dosing period. Animals were also observed for moribundity/mortality twice daily, prior to dosing and in the afternoon (at least 6 h apart), and only in the afternoon after the completion of the dosing period.
Rabbit study. Time-mated Pasteurella-Free New Zealand White rabbits (ϳ7 months old) were obtained from HRP, Inc. (Denver, PA). On 4 consecutive days, virgin females were paired with proven male breeders for approximately 1 h. The day the animals were observed to have mated was considered GD 0. Animals were identified (i.e., ear tagged) and weighed by the supplier (GD 0 weight range 3.15-4.54 kg). Upon arrival at the UIC AAALAC International accredited facility, the animals were at GD 1, GD 2, or GD 3. All animals were quarantined for at least 3 days before initiation of dosing, observed daily for signs of illness, and approved for use by the clinical veterinarian prior to being placed on study. The rabbits were singly housed in stainless steel cages (0.32 m 2 area and 38 cm height). Environmental controls were set to maintain temperature (61-69°F), humidity (30 -70%), and a 14-h-light/10-h-dark cycle. One hundred thirty g of Certified Rabbit Chow No. 5325 (PMI Feeds, Inc., St. Louis, MO) was offered on the days of measured food consumption. Tap water from an automatic watering system was available ad libitum from arrival to study termination.
Animals from each GD 0 subset was randomized by body weight into 4 groups, to result in 20 rabbits per group. The drug was administered by gavage once daily at doses of 15, 45, or 135 mg/kg/day (dose volume 2.5 ml/kg bw/day) over GD 7-20. The gavage procedure was accomplished by use of a rubber catheter. The control group received the vehicle (deionized distilled water) at the same dosing volume. The specific volume administered was adjusted on the basis of the animal's daily pre-dose body weight. Non-fasted body weights were recorded on GD 0 (by the supplier), on the day of randomization (GD 6), daily during the dosing period , and during the post-dosing period (GD 24 and 29). Food consumption was measured during the following 24-h intervals: GD 8/9, 11/12, 14/15, 17/18, 20/21, 23/24, and 28/29. Clinical signs were observed and recorded ϳ1-2 h post-dosing on the days of dosing, and each morning following completion of the dosing period. Animals were also observed for moribundity/mortality twice daily, prior to dosing and in the afternoon (at least 6 hours apart), and only in the afternoon after the completion of the dosing period.
Caesarean section. On GD 20 for rats and GD 29 for rabbits, animals were euthanized in random order by CO 2 asphyxiation (rats) or an intravenous injection of sodium pentobarbital (Ϸ50 mg/kg) via the marginal ear vein (rabbits). All animals were grossly examined. The abdominal and thoracic cavities were opened and the contents were examined for abnormalities. The ovaries and uteri were removed from each animal. In gravid animals, the number of corpora lutea on each ovary was recorded, and the ovaries were discarded after evaluation. The gravid uteri were weighed and opened. The number and location of implantation sites, viable and nonviable fetuses, and early and late resorptions were recorded from the distal ends of the left and right uterine horns to the cervix. Placentas were examined for abnormalities.
Uteri with no macroscopic evidence of implants were placed in a 10% ammonium sulfide solution for 10 min and examined for evidence of early embryolethality (Salewski, 1964) . Animals that were euthanized at an unscheduled necropsy were similarly examined. Following gross necropsy examinations, all carcasses of the dams were discarded. All viable fetuses were grossly examined, weighed, and sexed (rats only). The fetuses were then euthanized by intraperitoneal injection of a 40% solution of sodium pentobarbital (ϳ0.04 ml per rat fetus and approximately 0.4 ml per rabbit fetus). Nonviable fetuses were examined grossly, but were not sexed, weighed, or saved for visceral or skeletal evaluation.
Approximately half of all rat fetuses from each litter were fixed in Bouin's solution and subsequently examined for visceral anomalies under a stereomicroscope, using the Wilson free-hand slicing technique (Wilson, 1965) . The remaining rat fetuses from each litter were fixed in 95% isopropyl alcohol and subsequently eviscerated. The internal organs of all of the rabbit fetuses were examined in the fresh state for visceral anomalies, and the fetuses were sexed (Staples, 1974) . A mid-coronal slice into the cranium was made to expose and examine the brain, and the eyes were excised and examined. All of the rabbit fetuses were eviscerated, skinned, and then stored in 95% isopropyl alcohol. Fixed fetuses were macerated in a 2% potassium hydroxide solution, stained with Alizarin red-S, and cleared in 25% glycerin (Dawson, 1926) . Following skeletal evaluation, the preparations were stored in 50% glycerin/50% isopropyl alcohol.
Statistical analysis. The incidence or means and standard deviations of maternal and fetal observations were calculated and analyzed (Dunnett, 1955; Gad and Weil, 1988) . Calculations and statistical analyses of caesarean-section and fetal parameters were performed using the litter as the unit of analysis (Haseman and Hogan, 1975; Nishimura and Kast, 1989) . Maternal body weights and maternal body weight gains, uterine weights, calculated daily maternal food consumption (rats only), and fetal body weights were analyzed by one-way analysis of variance. If a significant F ratio was obtained ( p Ͻ 0.05), Dunnett's test was used for pair-wise comparisons to the vehicle control group. Calculated daily food consumption (rabbits, only) and the number of corpora lutea, implantations, resorptions (early, late, and total), viable and nonviable fetuses, and the percent preimplantation loss, postimplantation loss, and total implantation loss were compared using the Kruskal-Wallis test. If a significant effect was seen ( p Ͻ 0.05), the Mann-Whitney U test was used for pair-wise comparisons to the vehicle control group. The proportions of litters with abnormalities and the proportions of males in the various treatment groups were compared using Fisher's exact test and the Chi-square test, respectively. Caesarean section and fetal morphological data from pregnant animals that did not survive to the scheduled terminal sacrifice (i.e., animals that aborted or delivered prematurely) were not included in the statistical analysis. Caesarean section data from all animals were used to determine the incidence of pregnancy.
Rationale for dose selection. Doses for these studies were selected based on the results of oral dose range-finding developmental toxicity studies in rats and rabbits (Tables 1 and 2 ). Animals were mated over 2 consecutive days at Charles River Breeding Laboratories or HRP, Inc. Upon receipt at the UIC AAALAC International accredited facility, the animals were housed as previously described.
Rat dose range-finding study. DFMO was administered orally via gavage to rats (N, 5/group) over GD 6 -17 at dose levels of 0, 50, 125, 300, 800, or 2000 mg/kg/day. Caesarean sections and fetal gross observations were conducted on GD 20. Statistical analysis was conducted as previously described for maternal and caesarean section data and fetal sex ratios, body weights, and gross observations. In the dose range-finding study, maternal toxicity occurred at 800 and 2000 mg/kg/day as significant reductions in corrected body weight gains (i.e., gestation body weight gains less gravid uterine weights) and food consumption. Administration of 800 and 2000 mg DFMO/kg/day also resulted in complete early resorptions in all litters. Consequently, no fetuses were Rabbit dose range-finding study. Rabbits (N, 5/group) received 0, 30, 60, 120, 240, or 500 mg DFMO/kg/day orally via gavage on GD 7-20. Caesarean sections and fetal gross observations were conducted on GD 29. Statistical analysis was conducted as previously described for maternal and caesarean section data and fetal sex ratios, body weights, and gross observations. In the dose range-finding study, maternal toxicity was not observed at any dose level. At 500 mg/kg/day, complete early resorptions occurred in all litters, with no fetuses available for evaluation at this dose level. At 240 mg/kg/day, nonsignificantly increased numbers of nonviable fetuses and late resorptions were noted with significantly decreased numbers of viable fetuses (i.e., 13). Body weights were significantly reduced in these remaining fetuses and in fetuses at 120 mg/kg/day. Nonsignificantly-reduced fetal body weights were also noted at 60 mg/kg/day. Fetal development was unaffected at 30 mg/kg/day. There were no gross observations in the reduced number of fetuses at 240 mg/kg/day or in fetuses at 30, 60, or 120 mg/kg/day.
RESULTS

Rat Study
Maternal observations. There were no mortalities in the study, and no clinical signs attributed to treatment with DFMO. Administration of DFMO did not affect body weights or corrected body weights (i.e., GD 20 body weights less gravid uterine weights) at any dose level. There were no effects on body weight gains for the dosing or gestation periods (GD 6 -17 and GD 0 -20, respectively) or body weight gains corrected for gravid uterine weights (i.e., GD 0 -20 body weight gains less gravid uterine weights). Food consumption was comparable among all groups. Necropsy revealed singular, non-treatment-related findings of pancreatic cyst (1/25) at 30 mg/kg/day, lung abscess (1/25) at 80 mg/kg/day, and hydronephrosis (1/25) at 200 mg/kg/day. Placentas were normal in all litters.
Caesarean observations. There were no differences in reproductive indices in DFMO-treated groups compared to control animals (Table 3) . Nonsignificantly-reduced uterine weights in dams at 200 mg/kg/day were considered reflective of decreased fetal body weights. The numbers of implantations, resorptions (early, late, and total), and viable and nonviable fetuses were comparable among groups. There were no group differences in the percent preimplantation loss, postimplantation loss, and total implantation loss. Fetal sex ratios in the DFMO-treated groups were comparable with the control group.
Fetal observations. At 200 mg/kg/day, fetal body weights were significantly reduced (by litter and sex), and the number of litters with skeletal variations was significantly increased ( Tables 3 and 4 ). These variations included the presence of a 14th rudimentary rib, a 14th full rib, and/or a 27th presacral vertebrae in fetuses in 21, 5, and 17 litters, respectively, out of 23 total litters. The singular finding of an increased incidence of 14th rudimentary rib was also noted in a low number of litters at 30 and 80 mg/kg/day (4/22 litters in each group), although there were no fetal skeletal variations noted in the control litters. Including the current rat study, the historical incidence for this variation in control litters in our laboratory during 1994 -1998 is 18% (35/196) . Thus, the incidence of 14th rudimentary rib at 30 and 80 mg/kg/day (4/22; 18%) is consistent with the spontaneous occurrence of this anomaly in control animals. Additionally, although statistically significant (due to the lack of occurrence in the corresponding vehicle control group), this skeletal anomaly occurred in the absence of maternal toxicity or any other indication of developmental toxicity at these 2 dose levels. Thus, the presence of 14th rudimentary ribs at 30 and 80 mg/kg/day was considered a spontaneous variation, not indicative of developmental toxicity at those 2 dose levels. There were no drug-related external or visceral anomalies or skeletal malformations in fetuses in any group.
Rabbit Study
Maternal observations. There were no mortalities in the study and no clinical signs attributable to treatment with DFMO. Two animals (one at 15 mg/kg/day and one at 135 mg/kg/day) aborted and were necropsied on GDs 26 and 18, respectively. Blood was observed in the cage pan of both animals on the days the abortion was observed. One female at 15 mg/kg/day delivered prematurely and was immediately necropsied on GD 29. These sporadic or singular events were not considered treatment-related. Administration of DFMO did not affect body weights or corrected body weights (i.e., GD 29 body weights less gravid uterine weights). There were no differences in body weight gains for the dosing or gestation periods (i.e., GD 7-20 and GD 0 -29, respectively). Additionally, body weight gains corrected for gravid uterine weights (i.e., GD 0 -29 body weight gains less gravid uterine weights) were comparable among groups. There were no effects on food consumption at any dose level. Necropsy findings were limited to a singular observation of unascended, round kidney in one doe at 45 mg/kg/day. There were no abnormal observations in placentas in any group. Caesarean observations. Nonsignificant alterations in reproductive parameters were noted at 135 mg/kg/day. These alterations included slightly increased numbers of early resorptions and slightly decreased numbers of implantation sites (Table 5) . Consequently, a slight decrease in the number of viable fetuses was also noted. As a result of these effects, the percent preimplantation, postimplantation, and total implantation losses were nonsignificantly increased at 135 mg/kg/day. Significantly reduced uterine weights at 135 mg/kg/day were considered a consequence of reduced fetal weights. There were no effects of treatment on these parameters at 45 and 15 mg/kg/day. Fetal sex ratios in the DFMO-treated groups were comparable with the control group.
Fetal observations. Fetal weights (by litter and sex) were significantly decreased at 135 mg/kg/day (Table 5 ). There were no effects on fetal weights at 15 and 45 mg/kg/day. Fetal external, visceral, and skeletal examinations did not reveal any treatment-related malformations or variations at any dose level.
DISCUSSION
In the dose range-finding developmental toxicity studies, administration of DFMO during organogenesis caused embryolethality in rats at doses Ն 300 mg/kg/day and in rabbits at doses Ն 240 mg/kg/day. Thus, doses were chosen for the definitive oral developmental toxicity studies to ensure that sufficient numbers of fetuses were available for evaluation of potential teratogenic effects of DFMO when administered orally over 12 days in rats and 14 days in rabbits. In the 132 definitive study in rats, administration of DFMO over GD 6 -17 did not affect embryonic viability, but did result in reduced fetal body weights at the highest dose level (200 mg/kg/day). Rat fetuses, at 200 mg/kg/day, also displayed significantly increased incidences of 14th rudimentary rib (91%), 14th full rib (22%), and/or 27th presacral vertebrae (74%). In the definitive study in rabbits, administration of 135 mg DFMO/kg/day over GD 7-20 resulted in nonsignificantly increased numbers of early resorptions, nonsignificantly decreased numbers of implantation sites, and nonsignificantly decreased numbers of viable fetuses with significantly reduced body weights. Based on results of the dose range-finding study in rabbits, in which administration of DFMO produced developmental toxicity at doses as low as 60 mg/kg/day, the alterations in the main developmental studies noted at 135 mg/kg/day were considered treatmentrelated. Deleterious effects on embryonic development have been observed in previously conducted studies following administration of DFMO in drinking water to mice, rats, or rabbits (Fozard et al., 1980a,b; O'Toole et al., 1989) , intraperitoneally to rats (Reddy and Rukmani, 1982) , or subcutaneously to hamsters (Luzzani et al., 1982) . Fozard et al. (1980a,b) , Reddy and Rukmani (1981) , and Luzzani et al. (1982) observed that normal uterine ODC activity rose prior to and after implantation and then decreased significantly over the next few days. Concentrations of putrescine and spermidine, but not spermine, were also elevated during the peri-implantation period (Fozard et al., 1980a,b) . Administration of DFMO during the same period decreased or abolished ODC activity with concomitant reductions in putrescine and spermidine concentrations. Additional experiments in mice (Fozard et al., 1980a) and hamsters (Luzzani et al., 1982) demonstrated that ODC activity peaks on GD 8 in mice or GD 7 in hamsters (day of mating in both species, GD 1). These experiments also demonstrated that administration of DFMO on the peak day was more detrimental to embryonic development than on any other day of gestation. Thus, DFMO acts to arrest embryonic development in a timedependent manner during a short but critical period of gestation.
DFMO-induced fetal toxicity exemplified as reduced fetal body weights has also been noted in previously conducted studies in mice, rats, and rabbits at dose levels below those which were embryolethal (Fozard et al., 1980a,b; O'Toole et al., 1989) . In addition to effects on fetal body weights, an increased incidence of skeletal variations were observed by O'Toole et al. (1989) . In that study, treatment-related increases in the incidence of extra 14th rib and presacral vertebrae occurred in rat fetuses given 0.1% DFMO in drinking water (ϳ194 mg/kg/day) over GD 7-18 or 0.3% DFMO in drinking water (ϳ447 mg/kg/day) over GD 10 -18 (day of mating, GD 1). A slight but significantly increased incidence of extra presacral vertebrae occurred in rabbit fetuses in the 0.3% group (ϳ35 mg/kg/day) over GD 7-19 (day of mating, GD 1). In the present developmental toxicity studies, reduced body weights and findings of extra 14th rib were seen in rat fetuses exposed orally via gavage to 200 mg DFMO/kg/day over GD 6 -17, but skeletal variations such as extra presacral vertebrae were not observed in rabbit fetuses exposed orally via gavage to DFMO at doses as low as 15 mg/kg/day.
Although increased ODC activity and polyamine levels may be related to the process of calcification (Rath and Reddi, 1981; Vittur, 1986) , and administration of DFMO has been associated with suppression of ODC activity and subsequent inhibition of bone resorption (Lucas et al., 1989; Stern et al., 1990) , the skeletal variations noted in rat fetuses in the present study are also considered indicative of nonspecific fetal toxicity. The sporadic occurrence of supernumerary (i.e., extra and rudimentary) ribs and presacral vertebrae is highly variable in untreated animals (in-house historical database) and following treatment with a vehicle or chemical (Kavlock et al., 1985; Khera, 1984; Kimmel and Wilson, 1973) . It has been proposed that an increased incidence of these variants reflects toxicity but not teratogenicity at the observed dose level (Kimmel and Wilson, 1973; Wickramaratne, 1988) . The expression of fetal skeletal anomalies may be a consequence of maternal stress (Kavlock et al., 1985; Khera, 1984) , fetal growth suppression (O'Toole et al., 1989) , developmental delay (Wickramaratne, 1988) , and/or a species-specific spontaneous occurrence (Lansdown, 1976) . The presence of supernumerary ribs, especially extra ribs, at lower dose levels may be indicative of more severe drug effects at higher dose levels (Kimmel and Wilson, 1973) . In the present developmental toxicity study in rats, a treatment-related increased incidence of skeletal variants occurred in the 200-mg/kg/day group, while a severe drug effect (i.e., increased or complete resorptions) was noted at the higher dose levels in the dose range-finding studies.
Results from the definitive toxicity studies demonstrated that administration of DFMO to rats and rabbits for 12 and 14 days, respectively, during organogenesis produces developmental toxicity in the absence of maternal toxicity. In rats, reduced fetal body weights, accompanied by an increased incidence of skeletal variations of the rib and vertebrae, occurred at the high dose of 200 mg/kg/day. In rabbits, effects on embryonic and fetal viability with reduced fetal body weights in surviving fetuses occurred at the high dose of 135 mg/kg/day. Thus, in rats, the maternal NOEL was 200 mg/kg/day and the fetal NOEL was 80 mg/kg/day. In rabbits, the maternal NOEL was 135 mg/kg/day and the fetal NOEL was 45 mg/kg/day. The clinical dose in ongoing Phase II and III clinical trials is 0.5 g/M 2 (ϳ13 mg/kg for a 70 kg woman) (Crowell, personal communication) . Thus, a several-fold safety factor currently exists over the lowest fetal NOEL. In addition, these clinical trials require a negative pregnancy test and adequate birth control practices in order for women of childbearing potential to participate (Crowell, personal communication) .
